EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Ocuphire Pharma's enterprise value is $32.31 Mil.
Ocuphire Pharma's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $19.05 Mil. Therefore, Ocuphire Pharma's EV-to-Revenue for today is 1.70.
The historical rank and industry rank for Ocuphire Pharma's EV-to-Revenue or its related term are showing as below:
OCUP'
s EV-to-Revenue Range Over the Past 10 Years
Min: -0.71 Med: 34.8 Max: 483.02
Current: 1.7
During the past 5 years, the highest EV-to-Revenue of Ocuphire Pharma was 483.02. The lowest was -0.71. And the median was 34.80.
OCUP's EV-to-Revenue is ranked better than 82.98% of 1034
companies
in the Biotechnology industry
Industry Median: 8.205
vs OCUP: 1.70
As of today (2024-05-07), Ocuphire Pharma's stock price is $2.03.
Ocuphire Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.87. Therefore, Ocuphire Pharma's PS Ratio for today is 2.35.
Ocuphire Pharma EV-to-Revenue Historical Data
The historical data trend for Ocuphire Pharma's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Ocuphire Pharma's EV-to-Revenue
For the Biotechnology subindustry, Ocuphire Pharma's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ocuphire Pharma's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ocuphire Pharma's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Ocuphire Pharma's EV-to-Revenue falls into.
Ocuphire Pharma's current Enterprise Value is $32.31 Mil.
Ocuphire Pharma's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $19.05 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ocuphire Pharma's share price for today is $2.03.
Ocuphire Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.87.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ocuphire Pharma EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Ocuphire Pharma's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Ocuphire Pharma (Ocuphire Pharma) Business Description
Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Ocuphire's pipeline includes two small molecular product candidates targeting front and back of the eye indications. The Nyxol candidate is being developed for dim light or night vision disturbances, reversal of pharmacologically induced mydriasis, and presbyopia. The second product candidate, APX3330, is being developed for diabetic retinopathy and diabetic macular edema.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
OCUP has been successfully added to your 